Compare A O Smith Corp (AOS) vs GSK plc (GSK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
A O Smith Corp vs GSK plc — how do they compare? A O Smith Corp trades at $61 (market cap $8.33B), while GSK plc trades at $51.9 (market cap $103.72B). The key difference: GSK plc is far larger — about 12.5× A O Smith Corp's market cap, and GSK plc pays the higher dividend (3.4%). Which is the better fit depends on your goals.
| AOS | GSK | |
|---|---|---|
Market Cap | $8.33B | $103.72B |
Sector | Industrials | Health |
52-Week High | $80.47 | $61.18 |
52-Week Low | $55.78 | $36.20 |
Enterprise Value | $8.78B | $124.33B |
Dividend Yield | 2.35% | 3.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
A.O. Smith (AOS) trades at $60.44, up 2.41% today, with a bearish technical signal despite recent leadership changes. The company reported mixed Q1 2026 earnings, missing EPS estimates at $0.85 versus $0.94 expected, while maintaining solid profitability with a 13.84% net margin. Cash flow trends show improving operations, and the stock offers a dividend with a recent $0.36 payout announced.
The outlook is cautious due to earnings volatility and bearish technicals, but valuation appears reasonable with a P/E of 16.12. Risks include China market weakness and competitive pressures, while analyst consensus leans hold with a $68 price target suggesting modest upside potential from current levels.
GSK trades at $52.78, up 0.59% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS expected at $1.27. Revenue grew to $32.67B in 2025, with a net income margin of 17.78%. Recent news includes FDA approval for Utebzi and a $10.6B acquisition of Nuvalent to bolster its oncology pipeline.
GSK presents a balanced outlook with solid profitability and strategic growth in oncology, but faces risks from clinical trial setbacks and competitive pressures. Analyst sentiment is mixed, with 31% buy ratings, suggesting cautious optimism amid pipeline execution uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About A O Smith Corp
A.O. Smith Corporation manufactures and markets comprehensive lines of residential and commercial gas, gas tankless, and electric water heaters. Supplementary products include water heating equipment, condensing and noncondensing boilers, and water system tanks. The company's two operating segments are by geographic region: North America (majority of total revenue) and the Rest of the World. A material portion of sales in North America derive from replacing existing products, and the company utilizes a wholesale distribution channel and multiple selling locations. The Rest of the World segment sells primarily to Asian countries and operates sales offices to expand distribution and market its product portfolio.
Read more on AOS →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
